Drug Shortage Report for POTASSIUM PHOSPHATES INJECTION, USP

Last updated on 2023-04-13 History
Report ID 159355
Drug Identification Number 02139545
Brand name POTASSIUM PHOSPHATES INJECTION, USP
Common or Proper name Potassium Phosphates Injection, USP
Company Name FRESENIUS KABI CANADA LTD
Market Status MARKETED
Active Ingredient(s) POTASSIUM PHOSPHATE DIBASIC POTASSIUM PHOSPHATE MONOBASIC
Strength(s) 236MG 224MG
Dosage form(s) SOLUTION
Route of administration INTRAVENOUS INTRAVENOUS
Packaging size 50 ML
ATC code B05XA
ATC description I.V. SOLUTION ADDITIVES
Reason for shortage Disruption of the manufacture of the drug.
Anticipated start date
Actual start date 2023-03-01
Estimated end date 2023-05-01
Actual end date 2023-04-12
Shortage status Resolved
Updated date 2023-04-13
Company comments Product is on backorder. Effective March 1, 2023, allocations of Potassium Phosphates Injection, USP 3 mmol/mL Phosphorus SD Vial 15 mL to cover 100% of historical monthly demand of 15 mL and 100% of historical monthly demand of 50 mL at a 3:1 ratio. Please see communication for further details.
Health Canada comments
Tier 3 Status No
Contact Address 165 GALAXY BLVD, SUITE 100
TORONTO, ONTARIO
CANADA M9W 0C8
Company contact information

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v19 2023-04-13 English Compare
v18 2023-04-10 French Compare
v17 2023-04-10 English Compare
v16 2023-03-02 English Compare
v15 2023-03-01 French Compare
v14 2023-03-01 English Compare
v13 2023-02-15 French Compare
v12 2023-02-15 English Compare
v11 2023-01-02 French Compare
v10 2023-01-02 English Compare
v9 2022-11-03 French Compare
v8 2022-11-03 English Compare
v7 2022-09-01 French Compare
v6 2022-09-01 English Compare
v5 2022-08-04 French Compare
v4 2022-08-04 English Compare
v3 2022-05-02 English Compare
v2 2022-04-26 French Compare
v1 2022-04-26 English Compare

Showing 1 to 19 of 19